Tecentriq Demonstrates Increase In Overall NSCLC Survival in Phase III Study

When did stage 3B lung cancer become “early stage”?

My recent column about Merck’s television commercial for perioperative Keytruda left me with a question I could not shake.

FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC

FDA has granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.

September 18, 2026

Vol.52 No.34

Clinical Roundup

Zipalertinib + chemo meets primary endpoint in phase III REZILIENT3 trial in first-line EGFR exon 20 insertion mutation NSCLC

The REZILIENT3 trial, a global phase III clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations, met its primary endpoint of progression-free survival at a planned interim analysis.

September 11, 2026

Vol.52 No.33

Clinical Guest Editorial

Marketing hope before surgery: Does the new Keytruda commercial tell patients the whole story?

A patient recently asked me a question I suspect many thoracic surgeons will soon be hearing.

August 07, 2026

Vol.52 No.31

By Raja M. Flores

Clinical Trials & Tribulations

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

The recent retraction of the LungTIME-C01 randomized trial evaluating chrono-modulated immunotherapy in non-small cell lung cancer has ignited a vigorous debate regarding the promise of cancer chronotherapy.

July 31, 2026

Vol.52 No.30

By Zachary S. Buchwald and Michael C. Lowe

Drugs & Targets

FDA approves Jideytro for previously treated ROS1-positive non-small cell lung cancer

FDA approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received a prior ROS1 kinase inhibitor.

July 24, 2026

Vol.52 No.29

Tecentriq Demonstrates Increase In Overall NSCLC Survival in Phase III Study

YOU MAY BE INTERESTED IN

When did stage 3B lung cancer become “early stage”?

FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC

Zipalertinib + chemo meets primary endpoint in phase III REZILIENT3 trial in first-line EGFR exon 20 insertion mutation NSCLC

Marketing hope before surgery: Does the new Keytruda commercial tell patients the whole story?

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

FDA approves Jideytro for previously treated ROS1-positive non-small cell lung cancer

Renew today!

Subscriber content

Never miss an issue!

Login